NCT06933134 Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis
| NCT ID | NCT06933134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Tours |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-23 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-04-23 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.
Eligibility Criteria
Inclusion Criteria: . Age ≥ 18 years * Diagnosis of rheumatoid arthritis meeting ACR/EULAR 2010 criteria. * Candidates for a Low Dose regimen: on standard dose rituximab and with a good clinical response according to the referring rheumatologist. No maximum duration of use of standard-dose rituximab has been defined. * In the case of co-prescription of csDMARDs (Methotrexate, Leflunomide, Salazopyrine, Plaquenil), the dose must have been stable for 3 months. * If corticosteroids are co-prescribed, the dose should be ≤ 10 mg/d and stable for 3 months. Exclusion Criteria: * Other associated targeted disease-modifying therapy * Sjögren's syndrome or other associated inflammatory rheumatism * Fibromyalgia or other pathology having an impact on the assessment of disease activity * Any active haematological disease affecting lymphocytes (chronic lymphocytic leukaemia, Hodgkin's and non-Hodgkin's lymphomas, lymphoplasmacytic lymphoma, T lymphoma). * Opposition to data processing * No inclusio
Frequently Asked Questions
Who can join the NCT06933134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06933134 currently recruiting?
Yes, NCT06933134 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Tours to inquire about joining.
Where is the NCT06933134 trial being conducted?
This trial is being conducted at Tours, France.
Who is sponsoring the NCT06933134 clinical trial?
NCT06933134 is sponsored by University Hospital, Tours. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.